Theravance Inc  

(Public, NASDAQ:THRX)   Watch this stock  
Find more results for THRX
11.27
-0.05 (-0.44%)
Jan 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.04 - 11.44
52 week 10.60 - 32.91
Open 11.21
Vol / Avg. 726,881.00/961,963.00
Mkt cap 1.31B
P/E     -
Div/yield 0.25/8.87
EPS -0.98
Shares 115.37M
Beta 1.94
Inst. own 82%
Feb 4, 2015
Q4 2014 Theravance Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 18, 2014
Theravance Inc at Stifel Healthcare Conference
Nov 13, 2014
Theravance Inc at Credit Suisse Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -2129.23% -3587.66%
Operating margin -955.16% -3549.03%
EBITD margin - -3376.63%
Return on average assets -14.72% -32.52%
Return on average equity - -75.17%
Employees 241 -
CDP Score - -

Address

951 Gateway Blvd
SOUTH SAN FRANCISCO, CA 94080-7024
United States - Map
+1-650-2389600 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Theravance, Inc. is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. The Company operates in a single segment, which is focused on the discovery, development and commercialization of small molecule medicines across different therapeutic areas, including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The Company´┐Żs key programs include: RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, "FF/VI"), ANORO ELLIPTA (umeclidinium bromide/vilanterol, "UMEC/VI") and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with Glaxo Group Limited (GSK), and Long-Acting Muscarinic Antagonist program. Manufacturing of RELVAR/BREO ELLIPTA (FF/VI) and ANORO ELLIPTA (UMEC/VI) and for the MABA program is handled by GSK.

Officers and directors

William H. Waltrip Chairman of the Board
Age: 76
Bio & Compensation  - Reuters
Eric D'Esparbes Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
George B. Abercrombie Senior Vice President - Corporate Partnerships, Commercial
Age: 59
Bio & Compensation  - Reuters
Jeffrey D. Jonker Senior Vice President - Corporate and Business Development
Bio & Compensation  - Reuters
Junning Lee Senior Vice President - Technical Operations
Bio & Compensation  - Reuters
Frank Pasqualone Senior Vice President - Operations
Bio & Compensation  - Reuters
Theodore J. Witek Jr. Senior Vice President - Corporate Partnerships, Clinical and Medical Affairs
Bio & Compensation  - Reuters
Michael W. Aguiar President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Henrietta Holsman Fore Independent Director
Bio & Compensation  - Reuters
Catherine J. Friedman Independent Director
Bio & Compensation  - Reuters